Spotlight
Video

pan-HER inhibitor in non-small cell lung cancer, PF-00299804, as presented at the 35th European Society for Medical Oncology Congress section #1

Loading........
Description: pan-HER inhibitor in non-small cell lung cancer, PF-00299804, as
presented at the 35th European Society for Medical Oncology Congress section #1

The personalized approach to treating lung cancer started with the discovery of the benefits to targeting or inhibiting the Epidermal Growth Factor Receptor (EGFR), and it is now well known in the oncology community that 40 to 80 percent of non-small cell lung cancers (NSCLC) over-express EGFR, also known as Human Epidermal growth factor Receptor-1 (HER-1).[i]

In the past, drug development against the HER family in NSCLC has been focused mostly on small molecule selective and reversible tyrosine kinase inhibitors and monoclonal antibodies, with currently marketed HER-1 (EGFR) inhibitors targeting only one receptor.[ii],[iii] Today, new data is emerging about a next generation small molecule inhibitor of HER-1 (EGFR), -2 and -4 tyrosine kinases: PF-00299804, an oral, once-daily, pan-HER inhibitor.3
Shared By : europe_meeting_2010
Posted on : 10/20/10
Added : 7 years ago



More From europe_meeting_2010

Nothing found.